This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

VAST Data and CrowdStrike Deliver First-of-Its-Kind Cybersecurity Across the AI Operating System

VAST Data and CrowdStrike announced new integrations bringing enterprise-grade cybersecurity across AI infrastructure, data access, and AI pipelines. The partnership integrates CrowdStrike Falcon sensor natively into VAST's AI Operating System, with planned integrations for Falcon Next-Gen SIEM and Falcon Guardian (AI Detection and Response). Native Falcon sensor support is available today, while SIEM and Guardian integrations are in private preview.

Roth Capital Maintains Buy on CrowdStrike Holdings, Raises Price Target to $220

Roth Capital analyst Taz Koujalgi maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Buy and raises the price target from $200 to $220.

Scotiabank Maintains Sector Outperform on CrowdStrike Holdings, Raises Price Target to $265

AI’s Next Winners? Investor Bets on Snowflake, CrowdStrike and Palantir

Discover why Silvant Capital sees Snowflake, CrowdStrike, and Palantir winning the next wave of the AI boom.

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

H&R Block CEO Sells Over 2,800 Shares After the Stock Hit a 52-Week High

H&R Block CEO Curtis Campbell sold 2,833 shares (~$146,324) on August 31, 2026, as a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale is not concerning as it's a standard practice. H&R Block recently hit a 52-week high of $58.67, reporting strong FY2026 results with $3.9 billion in revenue (5% YoY growth) and forecasting $4.1-4.2 billion for FY2027, while raising its dividend by 10% for the ninth consecutive year.